We Target Chronic Inflammation
Recognizing the link between inflammation and numerous chronic diseases, Halia is pioneering targeting a specific inflammatory pathway, NLRP3, with an allosteric inhibitor to disrupt chronic inflammation. The goal of this method is to reduce inflammation and help reset this inflammatory pathway, potentially treating neurodegeneration and inflammatory diseases to improve quality of life and promote longevity.
Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.
Cancer
Live Better, Longer
We recognize that patients want to improve their health. Halia is dedicated to disrupting chronic inflammation to treat or prevent neurodegeneration and inflammatory diseases to improve quality of life and promote longevity.
NLRP3 Inflammasome:
Our drug targets to disrupt
chronic inflammation
Inflammation is an essential biological response of the human immune system that protects against disease. However, when dysregulated, inflammation can become a driver of disease by promoting a persistent, systemic immune response that fuels the development of many chronic diseases.1
One of the primary mechanisms mediating the persistent, systemic inflammatory response is activating a large protein complex called the NLRP3 inflammasome. The inflammasome activation produces pro-inflammatory signaling proteins, which contribute considerably to disease-causing inflammation.2
Science for longevity and quality of life
Our founders are renowned scientists with experience in drug discovery for oncology and neurodegeneration. We have made fundamental discoveries, identifying drug candidates that may potentially treat multiple disorders, including Alzheimer’s disease and other neurodegenerative disorders, as well as cancers and obesity.
Be a part of health history:
Schedule a meeting
Contact us
Participate in a trial
In the News
Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research
Fully Sponsored BioLabs Lab Space to Support Halia’s Next Phase of Development LEHI, Utah, March 11, 2025 /PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for chronic inflammation and obesity-related diseases, announced today that it has been awarded the Novo Nordisk Golden Ticket. The Novo Nordisk Golden Ticket – BioLabs European Award is...
Scrip Asks… What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances
Halia Therapeutics CEO Dr. David Bearss is quoted; Aging “The biopharma industry is undergoing a transformative shift, driven by longevity science and the need to manage chronic diseases,” said David Bearss, CEO of Halia Therapeutics. “GLP-1 agonist drugs have sparked new thinking in addressing aging populations and declining birth rates, marking the beginning of a new pivot toward therapies...
A ‘Wait-and-See’ Vibe Dominates Biotech’s Biggest Event of the Year
Executives attending J.P. Morgan conference don’t expect to find easy money in 2025 By Rowan Walrath C&EN Cartography Biosciences CEO Kevin Parker doesn’t see 2025 being much better than 2024 when it comes to financing opportunities for biotechnology companies like his. But like other executives who descended on San Francisco this week for the J.P. Morgan Healthcare Conference, he still took...